Skip to main content
. Author manuscript; available in PMC: 2020 Sep 1.
Published in final edited form as: Mol Cancer Ther. 2020 Jan 6;19(3):966–971. doi: 10.1158/1535-7163.MCT-19-0768

Figure 1. Schema of ‘triple-targeted’ genetic modifications of adenovirus to accomplish in vivo targeting of tumor endothelium.

Figure 1.

Liver un-targeting has previously been accomplished via genetic modification of hexon domains that can associate with serum factor X. Hexon ectodomain hypervariable regions (HVR7) of the vector was replaced base human adenovirus serotype 5 with the corresponding domains from human adenovirus serotype 3 (H5/H3). In addition, for transcriptional targeting, the 5’ upstream region of the therapeutic gene for roundabout 4 (ROBO4; endothelial specific promoter) was configured within the deleted adenovirus E1A/B site. The integrin targeting peptide RGD4C (CDCRGDCFC) was incorporated into HI loop of Ad fiber knob for transductional targeting.